SANIGEN Co., Ltd.

As of June 30, 2026, SANIGEN Co., Ltd. carries a market capitalization of 26.56B, placing it among publicly traded companies globally. Its enterprise value stands at 16.53B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, SANIGEN Co., Ltd. has 13.77M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 2.45, and the price-to-book ratio stands at 2.33.

These figures are as of June 30, 2026. The EV/Sales ratio of 2.65 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 16.53B versus a market cap of 26.56B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, SANIGEN Co., Ltd. maintains a current ratio of 2.35, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 37.88, indicating elevated leverage, while an interest coverage ratio of -10.86 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, SANIGEN Co., Ltd. posted a negative return on equity (ROE) of -51.82, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -27.00, reflecting losses generated across the asset base. Inventory turnover of 1.86 indicates how many times SANIGEN Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, SANIGEN Co., Ltd. recorded an income tax benefit of -32.73M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -5.18B and -5.15B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, SANIGEN Co., Ltd.'s stock has declined approximately 12.17% over the past 52 weeks. The 50-day moving average sits at 2,043.02, while the 200-day moving average is 1,919.14.

Over the twelve months ended June 30, 2026, SANIGEN Co., Ltd. generated 6.23B in revenue and converted that into -5.15B in net income, yielding earnings per share of -792.54. EBITDA reached -3.04B, while operating income came in at -3.97B.

As of June 30, 2026, SANIGEN Co., Ltd. holds 14.36B in cash and equivalents against 4.33B in total debt, resulting in a net debt position of -2.51B. Total book value stands at 11.42B, with working capital of 10.97B providing operational flexibility.

SANIGEN Co., Ltd. produced -2.41B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -74.94M in capital expenditures, free cash flow totaled -2.48B - equivalent to -313.30 per share.

Over the twelve months ended June 30, 2026, SANIGEN Co., Ltd. posted a gross margin of 42.56, reflecting its pricing power and cost economics. The operating margin of -63.68 and net profit margin of -82.56 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -19.80: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -56.22, meaning SANIGEN Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, SANIGEN Co., Ltd. has an Altman Z-Score of -0.83, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.